Lupin stock surges on robust sales in March quarter
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
lupin company
May 2023
March 2023
January 2023
December 2022
September 2022
August 2022
July 2022
June 2022
Lupin shares dip 4% on US FDA observations for Pithampur unit
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Lupin recalls blood pressure tablets in U.S.; stock up 3%
Lupin Pharmaceuticals Inc., the U.S. arm of the drug major, is voluntarily recalling four lots of Quinapril Tablets due to the presence of nitrosamine impurity.
What’s behind Indian pharma cos’ global acquisition spree
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
Lupin shares rise 4% on nod for Mirabegron tablets
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.
Sensex, Nifty to open higher; HDFC Bank, Lupin, IOC, Syrma SGS Technology, Dr. Reddy’s shares eyed
The Sensex and Nifty are set to open higher on the first day of September F&O contracts, tracking firm cues from global equities and positive trends on SGX Nifty Futures.
Sensex, Nifty to open in red; Tata Motors, NHPC, Lupin, JSW Steel, Wipro, Zomato shares eyed
The Sensex and Nifty are poised for a negative opening on Friday, following mixed cues from global peers and weak trends across SGX Nifty Futures.
Indian pharma majors to hit US growth bump in FY23
The revenue growth of about 16 leading Indian pharmaceutical companies is estimated to moderate to 6-7% in FY23, says ICRA.
Sensex, Nifty to slide; Wipro, Vedanta, Tata Power, Lupin, Crompton Greaves shares eyed
The Sensex and Nifty are set to bell the day in negative terrain, tracking weak cues from global peers and similar trends on the SGX Nifty futures.
